Product Innovation Zynex is actively developing advanced medical devices, such as the laser-based NiCO pulse oximeter, which targets more accurate blood oxygenation measurements, especially in patients with darker skin pigmentation. This focus on innovative, clinically superior products presents opportunities to engage health systems seeking cutting-edge diagnostic solutions.

Market Expansion With a broad product portfolio covering pain management, stroke rehabilitation, and cardiac monitoring, Zynex serves a diverse patient base. There is potential to increase sales by targeting hospitals, clinics, and home-care providers looking for non-invasive, FDA and CE-approved devices that address both acute and chronic conditions.

Recent Leadership Growth The appointment of a new CEO, Steven Dyson, along with recent strategic hires on the board and audit committee, signals a focus on corporate growth and innovation. This management momentum creates openings for collaborative ventures, product partnerships, and technology integrations to accelerate market penetration.

Recognition and Credibility Zynex has received multiple awards, including recognition on the Top Workplaces list and from U.S. News & World Report. Such industry recognition enhances credibility and opens doors for sales pitches to hospitals and clinics prioritizing trusted and award-winning medical suppliers.

Financial Range With revenues estimated between $100 million and $250 million, Zynex demonstrates solid financial stability, indicating capacity for scalable partnerships and larger procurement contracts. Its mid-size status offers flexibility for customized solutions to meet the needs of varied healthcare providers.